EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors |
| |
Authors: | Choi Young Lim,Soda Manabu,Yamashita Yoshihiro,Ueno Toshihide,Takashima Junpei,Nakajima Takahiro,Yatabe Yasushi,Takeuchi Kengo,Hamada Toru,Haruta Hidenori,Ishikawa Yuichi,Kimura Hideki,Mitsudomi Tetsuya,Tanio Yoshiro,Mano Hiroyuki ALK Lung Cancer Study Group |
| |
Affiliation: | Division of Functional Genomics, Jichi Medical University, Tochigi, Japan. |
| |
Abstract: | The EML4 (echinoderm microtubule-associated protein-like 4)-ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4 to 5% of non-small-cell lung cancers, and clinical trials of specific inhibitors of ALK for the treatment of such tumors are currently under way. Here, we report the discovery of two secondary mutations within the kinase domain of EML4-ALK in tumor cells isolated from a patient during the relapse phase of treatment with an ALK inhibitor. Each mutation developed independently in subclones of the tumor and conferred marked resistance to two different ALK inhibitors. (Funded by the Ministry of Health, Labor, and Welfare of Japan, and others.). |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|